PRNewsWire
01 Jun 2026, 19:31 UTC · 2h ago
Oculis Holding AG Investigation Initiated: Levi & Korsinsky Investigates the Officers and Directors of Oculis Holding AG (OCS)
PRNewsWire
01 Jun 2026, 19:31 UTC · 2h ago
Story key points
3 claims · impact-rated
Oculis Holding AG's Phase 3 DIAMOND trials for its lead product OCS-01 failed to meet the primary endpoint in diabetic macular edema. — The failure of a lead product's pivotal Phase 3 trial is a catastrophic clinical event that eliminates the primary path to revenue for the drug.
-1.00Oculis has decided to abandon the FDA filing for the diabetic macular edema indication entirely. — Abandoning the regulatory pathway means the company has conceded there is no viable path to market for this specific indication.
-0.90Law firm Levi & Korsinsky has initiated an investigation into Oculis for potential securities law violations regarding misleading statements about the OCS-01 program. — Legal investigations and potential class-action lawsuits create additional financial liability and governance risk beyond the clinical failure.
-0.40Ticker attribution
Continue reading
6 related stories
Search tags
Model heads
Phase 3 clinical trials failed, the company abandoned an FDA filing, the stock price crashed over 23%, and it is now under investigation for potential securities law violations.
Investors lost approximately 30% of investment value after Q2 FY2026 earnings missed expectations.
The stock collapsed on May 26, 2026, resulting in a loss of approximately 45% of investment value.
No ticker relationship head found.
Early access
News Impact Screener scores every headline against the stocks it moves — before the chart reacts. Join the early-access list and get alerted the moment a story hits your tickers.
Impact vectors
4 dimensions · 9 clusters
Market reaction
0 bid · 10 offered
No stock impact ranking available yet.
GlobeNewsWire
2h ago
